Product Description
ETX-0282 is an orally available BLI with a broad spectrum of activity against class A, C, and D serine ß-lactamases. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927146/)
Mechanisms of Action: LACTB Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innoviva
Company Location: BURLINGAME CA 94010
Company CEO: Pavel Raifeld
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Enterobacteriaceae Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12618000350224 | P1 |
Not yet recruiting |
Enterobacteriaceae Infections |
None |